PDCD1 and neoplasm: In a Panc02 subcutaneous tumor mouse model, CXCR4 antagonist BL-8040 combined with anti-PD-1 and irinotecan, fluorouracil and leucovorin reduced tumor growth by 58% compared with chemotherapy alone.